Histone methylation modification and diabetic kidney disease: Potential molecular mechanisms and therapeutic approaches (Review).

IF 8.3 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

ACS Applied Materials & Interfaces Pub Date : 2024-11-01 Epub Date: 2024-09-20 DOI:10.3892/ijmm.2024.5428

Peng Qu, Lanfang Li, Qi Jin, Donghai Liu, Yuan Qiao, Yijia Zhang, Qiuyue Sun, Shuman Ran, Zecheng Li, Tongtong Liu, Liang Peng

{"title":"Histone methylation modification and diabetic kidney disease: Potential molecular mechanisms and therapeutic approaches (Review).","authors":"Peng Qu, Lanfang Li, Qi Jin, Donghai Liu, Yuan Qiao, Yijia Zhang, Qiuyue Sun, Shuman Ran, Zecheng Li, Tongtong Liu, Liang Peng","doi":"10.3892/ijmm.2024.5428","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end‑stage renal disease, and is characterized by persistent proteinuria and decreased glomerular filtration rate. Despite extensive efforts, the increasing incidence highlights the urgent need for more effective treatments. Histone methylation is a crucial epigenetic modification, and its alteration can destabilize chromatin structure, thereby regulating the transcriptional activity of specific genes. Histone methylation serves a substantial role in the onset and progression of various diseases. In patients with DKD, changes in histone methylation are pivotal in mediating the interactions between genetic and environmental factors. Targeting these modifications shows promise in ameliorating renal histological manifestations, tissue fibrosis and proteinuria, and represents a novel therapeutic frontier with the potential to halt DKD progression. The present review focuses on the alterations in histone methylation during the development of DKD, systematically summarizes its impact on various renal parenchymal cells and underscores the potential of targeted histone methylation modifications in improving DKD outcomes.</p>","PeriodicalId":5,"journal":{"name":"ACS Applied Materials & Interfaces","volume":null,"pages":null},"PeriodicalIF":8.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414529/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Materials & Interfaces","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijmm.2024.5428","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end‑stage renal disease, and is characterized by persistent proteinuria and decreased glomerular filtration rate. Despite extensive efforts, the increasing incidence highlights the urgent need for more effective treatments. Histone methylation is a crucial epigenetic modification, and its alteration can destabilize chromatin structure, thereby regulating the transcriptional activity of specific genes. Histone methylation serves a substantial role in the onset and progression of various diseases. In patients with DKD, changes in histone methylation are pivotal in mediating the interactions between genetic and environmental factors. Targeting these modifications shows promise in ameliorating renal histological manifestations, tissue fibrosis and proteinuria, and represents a novel therapeutic frontier with the potential to halt DKD progression. The present review focuses on the alterations in histone methylation during the development of DKD, systematically summarizes its impact on various renal parenchymal cells and underscores the potential of targeted histone methylation modifications in improving DKD outcomes.

查看原文本刊更多论文

组蛋白甲基化修饰与糖尿病肾病：潜在的分子机制和治疗方法（综述）。

糖尿病肾病（DKD）是慢性肾病和终末期肾病的主要病因，其特点是持续蛋白尿和肾小球滤过率降低。尽管人们做出了大量努力，但糖尿病肾病发病率的不断上升凸显了人们对更有效治疗方法的迫切需求。组蛋白甲基化是一种重要的表观遗传修饰，其改变可破坏染色质结构的稳定性，从而调节特定基因的转录活性。组蛋白甲基化在各种疾病的发生和发展中起着重要作用。在 DKD 患者中，组蛋白甲基化的变化是介导遗传和环境因素相互作用的关键。以这些修饰为靶点有望改善肾脏组织学表现、组织纤维化和蛋白尿，是一个新的治疗前沿，有可能阻止 DKD 的进展。本综述侧重于 DKD 发病过程中组蛋白甲基化的改变，系统总结了其对各种肾实质细胞的影响，并强调了靶向组蛋白甲基化修饰在改善 DKD 预后方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Materials & Interfaces 工程技术-材料科学：综合

CiteScore

16.00

自引率

6.30%

发文量

4978

审稿时长

1.8 months

期刊介绍： ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.